
AnaptysBio's chairman's fund spent $17.2 million and holds 27.8% of the company
EcoR1 Capital, run by chairman Oleg Nodelman, bought Nov. 16 to 18, its first purchases since January 2025, filings show. AnaptysBio is suing for the rights to GSK's cancer drug Jemperli and expects a ruling by early 2027.
KeyVex News··5 min readFact-checked against 11 public records
KeyVex News··5 min readFact-checked against 11 public records
ANAB$47.06▲ 3.2%Close, Nov. 18. Prices from Tiingo.The short versionTap to readTap to close
- Since April, AnaptysBio mainly earns royalties on Jemperli, a cancer drug GSK sells. In court, it seeks the drug's rights back from GSK's unit Tesaro. GSK has called its allegations "entirely without merit."
- A Delaware judge heard the case in July and October. AnaptysBio expects a ruling in the fourth quarter or the first quarter of 2027.
- EcoR1, its largest holder, had not bought since January 2025. Its manager, Oleg Nodelman, is AnaptysBio's board chairman. After three days of buying, its funds hold 27.8% of the company.
- Separately, the $100 million stock buyback AnaptysBio's board approved in March was unused as of Sept. 30, the latest date reported. It expires Dec. 31.
- Next: Dec. 12, the FDA's date to decide on Quimilza, a skin-disease drug that would pay AnaptysBio a 10% royalty on sales.
The buy: The largest holder of AnaptysBio bought again. EcoR1 Capital, the fund manager run by Oleg Nodelman, AnaptysBio's board chairman, paid about $17.2 million for 374,580 shares Nov. 16 to 18, its Form 4 shows.Form 4Proxy A Form 4 is the report directors, officers and holders of more than 10% must file within two business days of most trades.SEC Nodelman has been chairman since August, AnaptysBio's report for the six months to June 30, filed in September, says.10-KT
The stake: EcoR1's funds now hold 8.25 million shares, 27.8% of the company, an amended Schedule 13D shows. Investors who own more than 5% of a company's stock file one, or a shorter form if they are passive holders.13D/A These were its first purchases since January 2025.Form 4Form 4 The Form 4 reports prices of $45.66 to $46.54 a share, about a third below the stock's highest close since the spin-off, $69.81 on July 13.Form 4Chart data EcoR1 said it bought "for investment purposes."13D/A The Form 4 does not mark the purchases as made under a trading plan, a schedule of trades set in advance.Form 4 AnaptysBio's quarterly report says no director or officer adopted or ended such a plan in the three months to Sept. 30.10-Q
Why it matters: Since April, AnaptysBio has mainly managed two royalty deals. The bigger one, on Jemperli, is now the subject of a lawsuit asking a Delaware judge to hand the drug's rights back to AnaptysBio.10-Q The company expects a ruling in the fourth quarter or the first quarter of 2027.8-K EcoR1's 13D gives the reason for its whole stake as "investment purposes."13D/A
AnaptysBio's stock since the spin-off, and the lawsuit's key datesDaily close, April 20 to Nov. 18, 2026 ▼ 7.6%Show chartHide chart
What AnaptysBio is now
On April 20, AnaptysBio spun off its drug-research business as First Tracks Biotherapeutics, giving holders one First Tracks share for each AnaptysBio share.10-Q What remains "manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda," it says.8-K
Jemperli is the bigger of the two. GSK reported $365 million of Jemperli sales in the quarter to Sept. 30, up 20%, AnaptysBio's results release says. Sales for the first nine months were $1.0 billion. AnaptysBio's royalty on sales between $1.0 billion and $1.5 billion in a calendar year is 12%.8-K
Not all of that money reaches AnaptysBio yet. In 2021 and 2024 it sold Sagard Healthcare Royalty Partners a share of its Jemperli royalties and milestones for $300 million in total.10-Q The company estimates about $270 million remains to be paid down under that deal, and expects that in the second half of 2027. It says its Jemperli royalties could top $390 million a year as early as 2029, at what it calls GSK's peak sales guidance for Jemperli used on its own.8-K
The smaller deal pays no royalties yet. The FDA is due to decide by Dec. 12 on Quimilza, a skin-disease drug licensed to Vanda Pharmaceuticals. If it is approved, AnaptysBio is eligible for a 10% royalty on its sales.10-Q
The lawsuit
AnaptysBio discovered the antibody that became Jemperli and licensed it in 2014 to Tesaro, which is now part of GSK.10-KT10-Q On Nov. 20, 2025, AnaptysBio asked Delaware's Chancery Court to declare that Tesaro had materially breached the license, and that GSK had interfered with it. Tesaro sued the same day.10-Q AnaptysBio says Tesaro broke the license's exclusivity terms by taking part in trials of rival drugs, including Merck's Keytruda, BioSpace reported.BioSpace Tesaro said AnaptysBio's own conduct was a breach that would let it end the license, take a permanent one, and cut the royalties and milestones it pays by 50%.GSK The court dismissed that claim on April 24.10-Q
The rest went to trial on July 14 to 17, with argument after the trial on Oct. 20. Tesaro asks for a declaration that it did not breach the license, and for an order barring AnaptysBio from ending it.10-Q AnaptysBio's 10-Q, its quarterly report, says what it asked for:
In our post-trial brief and during oral argument, we requested that the Court enforce the reversion provision in the Collaboration Agreement and order Tesaro to return dostarlimab rights to us.
GSK and TESARO are firmly of the view that these allegations are entirely without merit.
GSK said then that the April ruling "does not address the merits" of the main dispute.GSK The case is costly for AnaptysBio: its quarter's $11.6 million of general and administrative expenses included $4.8 million of legal costs for it.8-K
The buyback, as of Sept. 30
AnaptysBio's board approved a $100 million stock buyback in March. As of Sept. 30, none of it had been used, the quarterly report filed after the close on Nov. 12 shows. It expires Dec. 31.10-Q The same report shows 29.73 million shares outstanding on Nov. 9, down about 211,000 from Sept. 30. It does not give a reason, and its buyback figures run only to Sept. 30.10-Q The company had $153.0 million of cash and investments on Sept. 30.8-K
The only other open-market trade in insiders' Form 4s since the spin-off was a sale. Director Hollings Renton exercised options and sold 5,000 shares on Oct. 1, under a trading plan he adopted March 30, his Form 4 shows.Form 4
EcoR1's filing leaves its own next move open. Its 13D says it may buy more, or sell "at any time."13D/A
What to watch
The FDA's target date to decide on Quimilza, which would pay AnaptysBio a 10% royalty on sales.
AnaptysBio's $100 million buyback authorization expires.
The Delaware court's judgment on Jemperli's license, as AnaptysBio expects it.
AnaptysBio expects to finish paying Sagard from Jemperli royalties.
The paper trail
The filings behind this story, with the time EDGAR accepted the November 2026 ones.
| Filed (ET) | Form | Filer | What it shows |
|---|---|---|---|
| Jan. 2, 2025 | 4 | EcoR1 Capital | Bought 85,098 shares Dec. 30 to Jan. 2; holdings 7,880,094 shares. |
| Nov. 12, 4:16 p.m. | 8-K | AnaptysBio | Quarter results: Jemperli sales, the Sagard balance, a judgment expected Q4 2026 or Q1 2027. |
| Nov. 12, 4:21 p.m. | 10-Q | AnaptysBio | The lawsuit's history and AnaptysBio's request for the drug's rights. $100.0 million of the buyback still available on Sept. 30. |
| Nov. 18, 6:56 p.m. | 4 | EcoR1 Capital, Oleg Nodelman | Bought 84,120, 152,367 and 138,093 shares on Nov. 16, 17 and 18. |
| Nov. 18, 7:03 p.m. | 13D/A | EcoR1 Capital, Oleg Nodelman | Holds 8,254,674 shares, 27.8%. Bought for investment purposes. |
Sources
15 sources, 11 of them public records
Public records
- Form 4, EcoR1 Capital, LLC and Oleg Nodelman (purchases of Nov. 16 to 18, 2026)SEC EDGAR · Nov. 18, 2026
- Schedule 13D, Amendment No. 4, EcoR1 Capital, LLC, on AnaptysBioSEC EDGAR · Nov. 18, 2026
- Schedule 13D/A Exhibit 99.2: transactions in the past 60 daysSEC EDGAR · Nov. 18, 2026
- Form 4, EcoR1 Capital, LLC and Oleg Nodelman (purchases of Dec. 30, 2024 to Jan. 2, 2025)SEC EDGAR · Jan. 2, 2025
- AnaptysBio Inc., Form 10-Q for the quarter ended Sept. 30, 2026SEC EDGAR · Nov. 12, 2026
- AnaptysBio Inc., Form 8-K, Exhibit 99.1: fiscal first-quarter 2027 resultsSEC EDGAR · Nov. 12, 2026
- AnaptysBio Inc., definitive proxy statement (DEF 14A) for the Aug. 11, 2026 annual meetingSEC EDGAR · June 29, 2026
- AnaptysBio Inc., transition report on Form 10-KT for the six months ended June 30, 2026SEC EDGAR · Sept. 21, 2026
- Form 4, Hollings RentonSEC EDGAR · Oct. 2, 2026
- "TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc."GSK plc · Nov. 20, 2025
- "TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation"GSK plc · April 27, 2026
Rules and references
- Forms 3, 4 and 5U.S. Securities and Exchange Commission · Reference
Reporting
- "GSK's Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues"BioSpace · Nov. 21, 2025
Data
- Insider transactions for ANAB (SEC Form 4 data)KeyVex · through Nov. 18, 2026
- End-of-day prices for ANAB, and for SPY and QQQ on the chart (Tiingo)KeyVex · through Nov. 18, 2026
How we got these numbers
- Prices are end-of-day closes as traded, not adjusted for dividends. Daily moves are close to close. The chart starts on April 20, 2026, the day the First Tracks spin-off took effect: before it, AnaptysBio's price included the business it spun off, so earlier closes are not comparable. Our price source records the spin-off as a 3-for-2 split; it was not a split, and the chart shows none. The S&P 500 and Nasdaq 100 lines follow SPY and QQQ, rebased. The Filings switch shows the filing markers from KeyVex's AnaptysBio stock page: a selection, not every filing, and not only those tied to this story.
- EcoR1's purchase total is shares times the price its Form 4 reports for each day: $17,224,592.78. "First purchases since January 2025" means its holdings were 7,880,094 shares after its Jan. 2, 2025 purchase and, by its Nov. 18 Form 4, the same number just before Nov. 16.
- The 27.8% stake is EcoR1's, as its Schedule 13D states it: 8,254,674 shares of the 29,729,847 AnaptysBio reported outstanding on Nov. 9. "About a third below" compares the reported prices of $45.66 to $46.54 with the $69.81 close of July 13. On Sept. 30's share count, the same 8,254,674 shares would be 27.6%.
- Jemperli sales are GSK's figures as AnaptysBio's results release reports them. The Sagard balance, the royalty outlook and the timing of the judgment are AnaptysBio's estimates and expectations.





